ProCE Banner Activity

Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDS

Slideset Download
Download these slides from a live symposium for expert guidance on treatment options for higher-risk MDS and strategies for managing relapsed/refractory MDS.

Released: June 03, 2022

Expiration: June 02, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Karyopharm Therapeutics Inc.

Faculty Disclosure

Primary Author

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology Clinical Trials Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Medical Oncology and Hematology, Department of Internal Medicine
Yale School of Medicine and Yale Comprehensive Cancer Center
New Haven, Connecticut